Home/Pipeline/Tirzepatide (Zepbound)

Tirzepatide (Zepbound)

Obesity

ApprovedCommercial

Key Facts

Indication

Obesity

Phase

Approved

Status

Commercial

Company

Eli Lilly

About Eli Lilly

Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.

View full company profile

Therapeutic Areas

Diabetes Oncology Immunology Neuroscience Obesity Cardiovascular

Other Obesity Drugs

Drug	Company	Phase	Status
APJ Program	BioAge Labs	Preclinical	Active
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Approved	Recently approved in US
Amylin analogue (subcutaneous)	Novo Nordisk	Phase 1	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Phase 2	Active
VK2735 (subcutaneous)	Viking Therapeutics	Phase 3	Active
VK2735 (oral)	Viking Therapeutics	Phase 1/2	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
LTSE-2578	Structure Therapeutics	Preclinical	Lead Optimization
Survodutide (BI 456906)	Zealand Pharma	Phase 3	Active
ZP8396	Zealand Pharma	Preclinical/Phase 1	Active
Pemvidutide (ALT-801)	Altimmune	Phase 2	Active
PL7737	Palatin Technologies	Preclinical	Active